DailyIQ
|
Last updated2 minutes ago

BMRN·BioMarin Pharmaceutical Inc.

$65.05
-1.65 (-2.47%)
Overnight$65.07+0.02 (+0.03%)
High
$66.70
Open
$66.69
Market Cap
13.35B
52W High
$70.98
Low
$64.62
P. Close
$65.05
P/E
182.98
52W Low
$49.26
Fwd P/E
10.31
DailyIQ Est.
-
Inst. Ownership
0.1%
Short Interest
6.22%
Technical Score (1D)
82
BUY
News Sentiment
74
BULLISH
BioMarin’s Q2 earnings, released 16 hours ago, beat revenue expectations by 8 percent, driven by continued sales growth in its rare‑disorder portfolio. The stronger-than‑forecast revenue signals that the company’s precision‑medicine pipeline is gaining traction, which should support near‑term demand for its specialty drugs. However, the company’s focus on high‑priced therapies keeps it exposed to pricing scrutiny from payers and regulators, a risk that could temper future growth. The earnings beat also lifts investor confidence in BioMarin’s ability to monetize its rare‑disorder assets, potentially easing concerns about its valuation relative to peers. In the next 1–10 trading days, the market will likely weigh how the company’s guidance for the remainder of the year aligns with this positive revenue trend. Watch for any updates on regulatory approvals or pricing negotiations that could alter the company’s revenue trajectory. Also monitor the company’s pipeline updates, as new product launches could further boost sales or introduce additional pricing challenges. Finally, keep an eye on broader market sentiment toward specialty‑pharma stocks, as shifts in risk appetite could influence BioMarin’s stock relative to its peers.

EPS

EstBeatMiss
$0.67$0.87$1.07$1.27$1.47Q1'25Q1'26Q3'26
QtrEstActual+/−
Q3'26$1.38 - -
Q1'26$0.81$0.76-6.2%
Q1'25$0.95$1.13+18.6%

Revenue

EstBeatMiss
$698M$800M$901M$1.0B$1.1BQ1'25Q1'26Q3'26
QtrEstActual+/−
Q3'26$1.1B - -
Q1'26$771M$766M-0.6%
Q1'25 - $745M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BMRN Stock Snapshot

BMRN is currently trading at $65.07, giving BioMarin Pharmaceutical Inc. a market cap of 13.35B and a P/E ratio of 183.0. Today's range spans $64.62–$66.70, with shares opening at $66.69 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 74/100.

Over the past year BMRN has traded between $49.26 and $70.98 - the current price is +32.1% off the 52-week low and -8.3% from the high.

BioMarin Pharmaceutical Inc. (BMRN) is a large-cap in the broader market with 13.35B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 82/100 (BUY). Sentiment: bullish at 74/100. Price: $65.07 (in the upper portion of its 52-week range). The current P/E ratio stands at 183.0. The 52-week range of $49.26–$70.98 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

What makes BMRN's BUY setup (82/100) particularly actionable at 13.35B in the broader market capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $65.07 (in the upper portion of its 52-week range in $49.26–$70.98), with sentiment running bullish at 74/100, the setup rewards conviction-sized positioning more than it does speculative small bets.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles